SCHEMBL1027584

SCHEMBL1027584

O=C(O)Nc1cccc(NC(=O)CCc2cccc(Nc3nc(Cl)ncc3Cl)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.51
GAA P10253 2/20 0.51
CDK8 P49336 1/20 0.45
MET P08581 4/20 0.44
ALK Q9UM73 4/20 0.44
GFER P55789 1/20 0.43
EGFR P00533 2/20 0.43
JAK3 P52333 1/20 0.43
RHOA P61586 1/20 0.43
SELL P14151 1/20 0.43
SELP P16109 1/20 0.43
SELE P16581 1/20 0.43
BTK Q06187 2/20 0.42
HTT P42858 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
SIRT3 Q9NTG7 1/20 0.42
RAB9A P51151 1/20 0.42
ALDH1A1 P00352 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4334439 0.90 KMT2A (0.46) MAPTGAAMETALKEGFR
SCHEMBL13669789 0.89 TRPV1 (0.52) MAPTGAACDK8METALK
SCHEMBL4369271 0.86 CTSC (0.53) METALKEGFRJAK3BTK
SCHEMBL13623203 0.86 MET (0.48) MAPTGAACDK8METALK
SCHEMBL1082504 0.85 JAK3 (0.48) EGFRJAK3BTK
SCHEMBL4333056 0.85 EGFR (0.41) MAPTMETALKEGFRJAK3
SCHEMBL1025084 0.85 JAK3 (0.42) MAPTEGFRJAK3RHOABTK
SCHEMBL1024973 0.84 CTSC (0.40) EGFRJAK3RHOABTK
SCHEMBL1026953 0.84 GAA (0.47) MAPTGAACDK8METALK
SCHEMBL4364555 0.84 JAK3 (0.43) MAPTEGFRJAK3BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK MAPT 3239/4885GAA 2377/4885CDK8 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.